Flatiron Health collaborate with Sanofi to make clinical trials more efficient

Flatiron Health has entered a new partnership with Sanofi to redesign the clinical trial experience for sponsors, sites, and patients, in the field of oncology. 

Under the multi-study collaboration, the companies will focus on improving clinical trial data acquisition, delivery and quality. The firms will leverage site-facing technology capable of digitally transferring data from electronic health records (EHR) directly into the electronic data capture (EDC) system utilising Flatiron Health’s EHR-to-EDC product, Flatiron Clinical Pipe. The partnership will help clinical trial sites to spend less time on manual, high-volume data entry and downstream data resolution issues, enabling sites to spend more time with patients. Focusing on oncology the companies hope to accelerate the development of new treatments and help more patients with cancer. 

The collaboration will make it easier for sites to participate in Sanofi’s oncology clinical trials. In the initial Sanofi trial, the Flatiron technology for automated data push successfully transferred over 50% of study data from EHR to EDC. The companies will collaborate on data standards and mapping to expand the volume and types of data eligible for automated transfer.

“Flatiron’s expansion into the clinical research space is a natural progression for us. With the FDA’s guidance on interoperable technology that allows electronic transmission of relevant EHR data to the EDC system, we knew we had an opportunity with Flatiron Clinical Pipe to unlock the potential of data captured in the EHR, reduce the burden of clinical trials and accelerate research timelines,” says Alex Deyle, General Manager, Clinical Research, Flatiron Health. “We’re incredibly excited to collaborate and partner with forward-thinkers like Sanofi, who share our aspiration to leverage data and technology to transform clinical research. We look forward to working with the industry to solve a variety of challenges in the clinical research space—for the benefit of sponsors, CROs, sites and ultimately, the patients.”